

# Index

## A

- Actin filament, 43
  - Acute decompensated heart failure (ADHF), 137
    - echocardiographic assessment, 322
    - of cardiac output, 313
    - of left ventricular end-diastolic pressures, 312
    - of pulmonary pressures, 312
  - epidemiology, 309
  - hemodynamic evaluation, 311, 312
  - hemodynamic perturbations
    - cardiac output, 310
    - intracardiac filling pressures, 309
    - pulmonary capillary wedge pressure, 309
    - pulmonary vascular resistance, 310
    - right atrial pressure, 309
    - systemic vascular resistance, 310
  - hemodynamic tracings, 318
  - implantable hemodynamic monitoring, 313
  - left ventricular pressure tracing, 316
  - management principles, 315
    - inotropic therapy, 314
    - intravenous loop diuretic, 314
    - vasodilators, 314
  - pulmonary artery systolic pressure, 320
  - right heart catheterization, 313, 321
- Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF), 106
- Afterload
  - and arterial vasculature, 24–25
  - Anrep effect, 49
  - and cardiac efficiency, 31–33
  - cardiac performance, 24, 90
  - characteristics, 23
  - clinical practice
    - pulmonary vasculature, 33–34
    - respiratory cycle, 34
    - therapeutic reduction, 35–36
    - total peripheral resistance, 34–35
  - compliance, 25
  - concept, 24
  - definition, 23
  - elastance, 25
  - expression, 23
  - factors determining, 28
  - input impedance and characteristic impedance, 26–27
  - from invasive hemodynamics, 27–28
  - mismatch, 29–30, 37
  - mismatch in systolic heart failure, 35
  - physiology and theory, 24–28
  - reducing agent, 70
  - reducing strategy, 37
  - reflected pressure waves, 25–26
  - sarcomere shortening, 24
  - vs. stroke volume, 24- Aldosterone antagonists, 64–67, 70
- Aliskerin, 67
- $\alpha$ -receptors, 74
- Ambulatory hemodynamic monitoring, 205
- Angiotensin converting enzyme inhibitors, 70
- Angiotensin receptor blockers (ARBs), 62, 64
- Angiotensin receptor-neprilysin inhibitor (ARNi), 105, 107
- Angiotensin-converting enzyme (ACE), 61
- Angiotensin-converting enzyme inhibitors, 62–64
- Angiotensin II, 61
- Annulus paradoxus, 259
- Annulus reversus, 259
- Anrep effect, 45, 49
- Aortic flow, 215
- Aortic insufficiency echocardiography, 174–177
- Aortic pressure, 231
- Aortic regurgitation (AR)
  - anorectic drugs, 275
  - ascending aorta and root structure evaluation, 277
  - cardiac catheterization, 278
  - clinical case presentation, 275
  - echocardiographic characteristics, 277
  - epidemiology, 275
  - eponymous signs, 145
  - infective endocarditis, 275
  - left-anterior-oblique (LAO) projection, 278
  - LV size and systolic function, 277
  - physical examination, 276–277
  - PISA method, 277
  - pressure half-time, 277, 278, 287

- Aortic regurgitation (AR) (*cont.*)  
 regurgitant jet width, 277  
 severity, 277  
 valve anatomy assessment, 277
- Aortic stenosis (AS), 143, 151, 193  
 aortic valve area calculation, 273  
 cardiac catheterization, 274–275  
 clinical case presentation, 278–279  
 coronary angiography, 271  
 echocardiographic evaluation, 273  
 epidemiology, 271  
 low-flow/low-gradient, 274  
 maneuvers on, 149  
 physical examination, 276–277  
 physical finding, 145  
 risk factors, 272  
 stages, 167  
 symptoms, 272  
 transthoracic echocardiography, 271–273
- Aortic valve area (AVA), 164, 178  
 calculation, 273, 274
- Aortic valve repair/replacement, 286
- Aortic valve stenosis, 193
- Arrhythmia and beta-blockers, 77
- Arterial elastance, 90
- Arterial impedance, 24  
 compliance, 24  
 inertia, 24  
 resistance, 24
- Artifacts variety, 223
- Atrial contraction, 20
- Atrial fibrillation, 281
- Atrial septal defect (ASD), 189
- Atrial waveform, 7
- Atrio-ventricular node conduction (dromotropy), 73
- Atrioventricular septal defects, 190
- Austin Flint* murmur, 276
- Azotemia, 148
- B**
- Bainbridge reflex, 51
- Balloon atrial septostomy (BAS), 298
- Beck's triad, 249
- Benzothiazepines, 83
- Bernoulli equation, 158
- Bernoulli's theorem, 27
- $\beta$ -adrenergic receptors, 73
- Beta-blockers (BBs), 20  
 cardiac output with, 75  
 central pressure effects, 76  
 compensatory tachycardia, 249  
 coronary artery disease, 77  
 hemodynamic effects, 75–76  
 non-vasodilating, 75  
 pharmacological characteristics, 74–75  
 propranolol, 73  
 therapeutic indications  
 arrhythmia, 77  
 heart failure, 77  
 hypertension, 76–77  
 vasodilating properties, 75
- $\beta$ -receptors, 74
- $\beta$ 1-receptors increases heart rate (chronotropy), 73
- Bioimpedance spectroscopy, 18
- Biomarkers, 206–207
- Bioreactance, 215
- Blood oxygen level-dependent (BOLD) CMR, 200
- Bowditch/Treppe effect, 45
- Bradykinin metabolism, 106
- C**
- Calcific constrictive pericarditis, 265
- Calcium  
 in cytosol binds, 43  
 in excitation-contraction coupling, 44  
 inflow via voltage-gated L-type calcium channels, 49  
 influx of, 42
- Calcium channel blockers (CCBs)  
 cardiac contractility effect, 80  
 cardiovascular hemodynamics, 78–80  
 classification, 78  
 definition, 77  
 dihydropyridine, 80, 81  
 effect of, 79  
 endothelial and anti-atheromatous effects, 80–81  
 evolution, 79  
 on hemodynamics, 79  
 left ventricular filling, 80  
 left ventricular mass, 80  
 mechanism of action, 78  
 negative inotropic effects, 83  
 non-dihydropyridine, 82–83  
 outcome data, 81–82
- Capillary hypertension, 150
- Cardiac amyloidosis, 186, 267  
 late gadolinium enhancement (LGE), 262
- Cardiac catheterization, aortic stenosis, 274
- Cardiac contractility, CCBs, 80
- Cardiac contraction and relaxation, 44
- Cardiac cycle, 5
- Cardiac hemodynamics, 151
- Cardiac index, 313, 315, 321
- Cardiac magnetic resonance (CMR)  
 cardiac sarcoidosis, 262  
 hemochromatosis, 263
- Cardiac output  
 changes in, 52  
 circulatory hemodynamics, 52–53  
 definition, 51  
 determination methods  
 Fick principle, 55–56  
 thermodilution method, 54–55  
 transpulmonary thermodilution technique, 56  
 ventriculography, 56  
 factors of, 53  
 hemodynamic disturbances, 53  
 hemodynamic profile, 57  
 nitroprusside, 57

- normal, 231–234
  - oxygen consumption, 58
  - preload, 51
  - preload vs. contractility, 52
  - and system vascular resistance, 163
  - thermal method, 54
  - thermodilution method, 58
  - Cardiac preload, *see* Preload
  - Cardiac sarcoidosis, 262
  - Cardiac syndrome X, 353, 354, 359, 360
  - Cardiogenic shock (CS), 53, 146, 337–340
    - hemodynamic criteria, 117–119, 348
    - right ventricular infarction, 349
  - CardioMEMS™ HF implantable hemodynamic monitoring system, 208
  - Cardiomyopathies, 194
  - Cardioprotection, 73
  - Cardioselectivity, definition, 74
  - Cardiovascular diseases
    - ACEI in, 65
    - aldosterone antagonists in, 66
    - ARBs in, 66
    - dual RAAS blockade in, 67
    - vasodilators in, 69
  - Cardiovascular hemodynamics
    - aldosterone antagonists, 64–67
    - angiotensin receptor blockers, 64
    - angiotensin-converting enzyme inhibitors, 63–64
    - combination therapy, 68
    - direct renin inhibitor, 67
    - dual RAAS blockade, 67–68
    - nesiritide, 70
  - Carvallo sign, 149
  - Catecholamines, 44
  - Catheter
    - central venous, 6
    - retrograde passage of, 12
    - Swan-Ganz, 9
  - Central venous pressure, 6, 7, 19
    - waveform, 7
  - CentriMag, 123, 132
  - Chamber
    - anatomy and function, 4–6
    - average pressures, 6
  - Chronic pulmonary venous, 150
  - Circulatory shock, 53
  - Computed tomography (CT)
    - advantages, 184
    - clinical applications, 189–200
    - contrast media, 189
    - disadvantages, 184
    - ECG-triggering, 188–189
  - Computed tomography myocardial perfusion (CTP), 199
  - Congenital bicuspid valve disease, 277
  - Congenital heart disease (CHD)
    - echocardiographic assessment, 333, 334
    - management, 301
  - Congenital heart disease (CHD)-associated PAH, 290
  - Constrictive pericarditis (CP), 195, 251
    - cardiac magnetic resonance imaging, 261
    - causes, 255, 268
    - chest radiography, 256
    - computed tomography, 261
    - Doppler echocardiography, 256
    - electrocardiography, 256
    - features, 268
    - global longitudinal strain, 260
    - hemodynamic assessment, 264
    - history/clinical presentation, 255
    - Kussmaul's sign, 269
    - left and right heart catheterization, 264, 268
    - mitral annular velocity, 258
    - mitral inflow, 269
    - pathophysiology, 251–252
    - pericardial knock, 268
    - physical examination, 255
    - pulmonary and hepatic venous flows, 259
    - tissue Doppler imaging (TDI), 256
    - trans-mitral flow velocity pattern, 256
    - transthoracic echocardiography, 256
    - ventricular septal shift, 256
  - Continuous cardiac output method, 54
  - Continuous pulmonary vascular pressure monitoring., 207–208
  - Contractility
    - in cardiac disease
      - heart failure, 46
      - ischemia, 45
    - characteristics, 41
    - clinical measurement, 41
    - concept of, 42
    - medications and
      - digoxin, 48
      - dobutamine, 46–47
      - dopamine, 47
      - epinephrine (adrenaline), 47–48
      - isoproterenol, 48
      - milrinone, 48
      - norepinephrine, 47
    - physiology, 42–45
  - Corlanor, *see* Ivabradine
  - Coronary angiography, 197–200, 351
  - Coronary artery bypass grafting (CABG), 140
  - Coronary artery disease, beta-blockers, 77
  - Coronary flow reserve (CFR), 352
    - definition, 352
    - Doppler-derived, 352
    - relative, 353
  - Corrigan sign, 145
- D**
- Depolarization, 42
  - Diastolic function, 192
  - Diastolic murmur, 145
  - Diastology, 192
  - Digoxin, 48–49
  - Dihydropyridine CCBs, 81
  - Diltiazem, 83, 93
  - Direct Fick method, 293

Direct renin inhibitors (DRI), 62, 67  
 Distributive shock, 337, 338, 341–342  
 Dobutamine, 20, 46–47, 94–95  
 Dobutamine stress echocardiography (DSE), 274  
 Dopamine, 47, 97  
 Doppler-derived CFR, 352  
 Dual RAAS blockade, 67–68  
 Durable mechanical circulatory support  
   durable LVAD systems, 127–128  
   right ventricular support, 130–132  
 Durozier's sign, 276

## E

ECG-triggering, 201  
 Echocardiography, 206  
   Bernoulli equation, 156, 158  
   color Doppler, 158  
   continuous wave vs. pulse wave Doppler, 156–158  
   convective acceleration, 159  
   definition, 155  
   Doppler form, 157  
   Doppler principle, 155, 156  
   intracardiac pressures  
     cardiac output and system vascular resistance, 163  
     pulmonary artery, 162  
     pulmonary capillary wedge/left atrial pressure,  
       162–163  
     right atrial pressure, 159–161  
     right ventricle, 161–162  
   physics of, 155–159  
   valve disease  
     aortic insufficiency, 174–177  
     aortic stenosis, 164–168  
     mitral regurgitation, 171–174  
     mitral stenosis, 168–171  
 Effusive-constrictive pericarditis (ECP), 267  
 Ejection fraction (EF)  
   definition, 41  
   reference values, 41  
 Elastance, 19  
   variations in, 27  
 Electric conductance based methods, 211  
 Electrical impedance, 26  
 Electrodes, tetrapolar system, 210  
 End-diastolic pulmonary artery pressure, 178  
 End-diastolic volume, 20  
 Endhole catheters, 231  
 Endogenous fluid challenge, 20  
 Endothelial and anti-atheromatous effects, 80–81  
 Entresto, *see* Sacubitril/valsartan  
 Epinephrine (adrenaline), 47–48, 97  
 Esmolol, 93  
 Exercise, preload, 8  
 Exertional dyspnea, 205, 298, 299

## F

Familial restrictive cardiomyopathy, 254  
 Fatal and nonfatal stroke, 82

Fick cardiac output, 55–57  
 Fick method, 231  
 Fractional Flow Reserve (FFR), 199, 359, 360  
   acute myocardial infarction, 356  
   bifurcation lesion, 356  
   definition, 354  
   vs. iFR method, 357, 358  
   left main coronary artery stenosis, 355  
   limitations, 357  
   measurement, 359  
   mortality and adverse cardiovascular event (MACE)  
     rates, 354  
   multi-vessel CAD, 354  
   percutaneous coronary intervention (PCI), 355  
   post PCI, 356  
   saphenous vein graft (SVG) lesions, 356  
 Frank-Starling principle, 89  
 Frequency-dependent activation, 45

## G

Gallivardin's phenomenon, 272  
 Gorlin equation, 274  
 Gorlin formula, 233

## H

Hakki equation, 275  
 Hales, Stephen, 24  
 Harlequin syndrome, 126  
 Heart failure  
   beta-blockers, 77  
   chronic systolic, 61, 70  
   definition, 53  
   estimation, 309  
   and myocardial infarction, 67  
   RAAS activation, 105  
   systolic, 63  
 Heart failure with preserved ejection fraction  
   (HFpEF), 26  
 Heart failure with reduced ejection fraction (HFrEF), 106  
   ivabradine in, 112  
   with LVEF  $\leq$  35%, 112  
 Heart murmur, 138, 145  
 HeartMate II (HMII), 127  
 HeartMate 3 (HM3), 127  
 HeartWare HVAD, 127  
 Hematemesis, 147  
 Hemochromatosis, 263  
 Hemodynamic assessment  
   aortic stenosis, 273  
   pulmonary hypertension, 297  
 Hepatic vein expiratory diastolic reversal ratio, 260  
 Hepatic vein tracing, 246  
 Hepatojugular reflux (HJR), 138  
 Hepatomegaly, 138  
 Hill's sign, 276  
 H-ISDN, 69  
 Hybrid reference units (HRU), 34  
 Hydralazine, 69

- Hypertension  
 ARBs in, 64  
 and beta-blockers, 76–77  
 essential, 63
- Hypertrophic cardiomyopathy (HCM), 149, 186, 272  
 maneuvers on, 149  
 obstructive, 151
- Hypotension, 141  
 pericardial effusion and, 242
- Hypovolemia, 148
- Hypovolemic shock, 53, 337, 338, 340–341
- I**
- Idiopathic pulmonary arterial hypertension (iPAH), 290
- Impedance  
 measurements, 214  
 concept, 27  
 waveforms, 211
- Impella  
 characteristics, 121  
 extracorporeal pumps, 122–126  
 hemodynamics, 121  
 limitations, 121  
 study data, 121–122
- Impella RP, 130
- Implantable cardioverter defibrillators (ICDs), 209
- Indirect Fick method, 293
- Infective endocarditis, aortic regurgitation, 275
- Inferior myocardial infarction, 20
- Inhaled nitric oxide (iNO), 296
- Inotropes, 94
- Instantaneous Free-Wave Ratio (iFR), 357  
 vs. FFR, 357, 358
- Intra-aortic Ballon Pump (IABP), 146  
 characteristics, 119–121  
 hemodynamic effects, 119–120  
 limitations, 120–121  
 study data, 121
- Intra-aortic balloon counterpulsation augments, 37
- Intracardiac (IC) shunts, 325  
 cardiac CT, 328  
 cardiovascular magnetic resonance, 328  
 color flow Doppler, 326  
 Fick's method, 331  
 hemodynamic significance, 326  
 invasive oxymetric measurement, 334, 335  
 left ventricle outflow tract, 327  
 mixed venous blood, 333, 334  
 MRI, 328  
 oxygen saturation run study  
 blood sampling, 331  
 mixed venous oxygen saturation, 332  
 pulmonary to systemic flow ratio, 332, 333  
 oxymetric saturation run study  
 blood sampling, 331  
 radionuclide scintigraphy, 328  
 right ventricle outflow tract, 327  
 transesophageal echocardiography, 326  
 transthoracic echocardiography, 326, 327  
 velocity encoded cine MR, 328  
 ventricular septal defect, 333, 334
- Intracardiac impedance monitoring, 212–215
- Intracardiac pressure waveforms, 9
- Intracardiac sensors/monitoring devices  
 intrathoracic impedance, 209  
 Left atrial pressure sensors, 209  
 right ventricular pressure sensors, 208–209
- Intracoronary hemodynamic assessment  
 coronary flow reserve, 352–354  
 Fractional Flow Reserve (*see* Fractional Flow Reserve (FFR))  
 Instantaneous Free-Wave Ratio, 357–358
- Intrapericardial pressure, 240, 241
- Intrathoracic blood volume (ITBV), 17
- Intrathoracic impedance monitoring, 209
- Intrathoracic pressures, 245
- Intravascular visualization techniques, 351
- Intrinsic contractile function, 90
- Ischemia, 188, 200
- Ischemic cardiomyopathy  
 cardiac performance, 101  
 hemodynamic profiles, 101  
 management, 100
- Isoproterenol (isoprenaline), 48, 95
- Isosorbide dinitrate, 69
- Ivabradine, 105  
 approval timeline of, 112  
 benefit, 111  
 bradycardia frequency, 111  
 efficacy, 112  
 excretion, 110  
 indications, 112  
 mechanism of action, 110  
 pharmacology, 109
- J**
- Jugular venous pressure (JVP), 137
- Jugular venous waveform patterns, 140
- K**
- Kallikrein-kinin system, 63
- Kaplan-Meier cumulative event curves, 113
- Kussmaul's sign, 245, 255, 264, 269
- L**
- Law of Laplace, 52
- LCZ696 levels, 108
- Left heart catheterization  
 left ventricular pressure, 231  
 PCWP, 230, 231  
 pressure measurements, 227–231  
 pulmonary artery pressure, 230  
 right atrial pressure, 227–229  
 right ventricular pressure, 229  
 technique, 227

- Left ventricular assist device (LVAD)  
 hemodynamics, 128, 129  
 intervention, 131  
 pump parameters, 128
- Left ventricular (LV) preload estimation, 89
- Left ventricular end-diastolic pressure (LVEDP), 3, 6, 10, 11, 18
- Left ventricular end-systolic elastance, 90
- Left ventricular filling, 80
- Left ventricular hypertrophy, 19
- Left ventricular mass (LVM), 80
- Left ventricular outflow tract (LVOT) gradient, 149
- Left ventricular pressure curves, 42
- Left ventricular systolic dysfunction, 285, 286
- Levosimendan, 96
- Lipomatous hypertrophy, 261
- Lipophilicity/hydrophilicity, 75
- Low-flow/low-gradient aortic stenosis, 274
- M**
- Magnetic resonance imaging (MRI)  
 advantages, 184  
 delayed enhancement imaging, 188  
 disadvantages, 184  
 myocardial tagging, 185  
 phase-contrast imaging, 185  
 physics overview, 183–184  
 tissue characterization, 188  
 volumetric and functional assessment, 185–188
- Mechanical ventilation, positive end-expiratory pressure, 20
- Milrinone (PDE-3 Inhibitor), 48, 95–96
- Mitral commissurotomy, 151
- Mitral regurgitation (MR), 19, 138, 284, 287  
 assessment, 172  
 characteristics, 171–174  
 classification, 283  
 clinical case presentation, 282–283  
 Color Doppler imaging, 284  
 echocardiography, 283, 284  
 grading, 285  
 invasive hemodynamic assessment, 285  
 physical examination, 283  
 PISA method, 173, 284  
 pulsed-wave Doppler, 285  
 severity, 171  
 signs, 174  
 vena contracta, 174  
 ventriculography, 285
- Mitral stenosis (MS), 150, 281  
 assessment, 169, 233  
 cardiac catheterization, 281–282  
 causes, 168–169  
 clinical case presentation, 278–279  
 echocardiography, 280–281  
 epidemiology and pathophysiology, 279  
 physical examination, 279–280  
 stages, 170
- Mitral valve inflow pattern, 245
- Mitral valve prolapse (MVP), 138–139
- M-mode echocardiography, 256
- Multi-slice computed tomography (MSCT), 192
- Murmur with squatting, 151
- Muscarinic (M2) receptors, 44
- Myocardial contractility, 73  
 definition, 41 (*see also* contractility)
- Myocardial infarction (MI), 146
- Myocardial ischemia, 45
- Myocardial oxygen consumption, 31
- Myocardial perfusion reserve (MPR), 200
- Myocardial tagging, 185
- Myocardium, 237
- Myofiber shortening, 23
- N**
- Natriuretic peptide system (NPS), 105
- Nepilysin (NEP), 106, 108
- Nesiritide, 70, 93
- Nitroglycerin (NTG), 91–93
- Nitroprusside, 37, 57
- Nonejection click, 139
- Noninvasive cardiac imaging, 183
- Noninvasive hemodynamic (HD) monitoring, 205
- Non-ischemic cardiomyopathy  
 course of action, 100  
 hemodynamic profiles, 100
- Nordic Diltiazem (NORDIL) trial, 83
- Norepinephrine, 47, 97, 310
- North-South syndrome, 126
- N-terminal pro-B-type natriuretic peptide (NT-proBNP)  
 concentration, 108–109
- O**
- Obstructive shock, 337, 338, 342
- Ohm's law, 52
- Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE), 106
- P**
- PA denervation, 298
- Pacemakers, 209
- PARADIGM-HF investigators, 108
- Partial anomalous pulmonary venous return (PAPVR), 191, 301
- Partial carbon dioxide rebreathing technique, 215–216
- Passive leg raising (PLR), 8
- Patent ductus arteriosus (PDA), 190, 191, 334
- Peak-to-peak gradient, 274
- Percutaneous coronary intervention (PCI), 354, 359, 360
- Pericardial constriction, 140
- Pericardial disease, 194–195
- Pericardial effusion classification, 240
- Pericardial knock, 141
- Pericardial pressure-volume relationship, 252
- Pericardial “stripping”/pericardiectomy, 252

- Pericardial tamponade stages, 241  
 Pericardiocentesis, 246, 248  
 Pericarditis, 240  
 Pericardium, 252, 253  
   anatomy, 237  
   Doppler evaluation, 238  
   parietal and visceral, 237  
 Phase-contrast imaging (PCI), 185, 200  
 Phenylalkylamines, 82  
 Phenylephrine, 98  
 Physical exam findings, 291  
 Plasma renin activity, 71  
 Preload  
   clinical assessment, 10, 16  
   in clinical practice  
     invasive assessment techniques, 16  
     invasive hemodynamics, 15  
     noninvasive assessment techniques, 15–16  
   concept, 4  
   decreasing agent, 70  
   definition, 3  
   dependency and pressure–volume loops, 12–14  
   factors determining, 4  
   filling pressure, 90  
   LaPlace's equation, 3  
   left ventricular, 12, 89  
   left ventricular end-diastolic pressure, 11, 18  
   mathematical expression, 3  
   as physiological concept, 4  
   physiology and theory, 4–6  
   as primary determinant, 36  
   pulmonary capillary wedge pressure, 10–11  
   quantification, 12  
   reserve and venous system, 7–8  
   and respiratory cycle, 8–9  
   right atrial pressure, 7  
   right ventricular, 89  
   surrogate parameter, 18  
   tangible and measurable representation, 3  
 Premature ventricular complex (PVC), 150  
 Pre-pericardiocentesis, 239  
 Pressure  
   atrial, 5  
   parameters of, 3  
   passive, 3  
   ventricular, 3  
 Pressure half-time (PHT), 169  
 Pressure-volume loops, 90  
 Primary mitral regurgitation, 283  
 Propranolol, 73  
 Prospective Randomized Amlodipine Survival Evaluation (PRAISE 2) trial, 83  
 Proximal isovelocity surface area (PISA) method  
   aortic regurgitation, 277  
   mitral regurgitation, 284  
 Pulmonary arterial hypertension (PAH), 289  
   acute vasoreactivity testing, 304  
   causes, 290  
   connective tissue disease -associated, 290  
   drugs, 297  
   hemodynamics, 304  
   medical management, 297–298  
   prevalence, 290  
   pulmonary capillary wedge pressure, 294  
   pulmonary vasoreactivity testing, 296  
   right heart catheterization, 293  
   saturation, 305  
   treatment, 305  
 Pulmonary artery catheter, 285  
   findings, 244–245  
   indications for use, 322  
 Pulmonary artery catheterization, 279  
 Pulmonary artery diastolic (PAD) pressure, 10  
 Pulmonary artery monitoring, 207–208  
 Pulmonary artery systolic pressure (PASP), 258  
 Pulmonary capillary wedge pressure  
   (PCWP), 10, 11, 137, 321  
 Pulmonary capillary wedge pressure  
   waveform, 9–10  
 Pulmonary hypertension (PH), 289  
   cardiac magnetic resonance, 292  
   chest radiography, 292  
   clinical presentation, 291–292  
   computed tomography, 292  
   CT angiography of chest, 304  
   epidemiology, 289–291  
   hemodynamic assessment, 297  
   hemodynamic evaluation, 293  
     euvoletic states of low/normal CO, 293  
     pulmonary capillary wedge pressure, 294  
     pulmonary vascular resistance, 294  
     RA pressure waveform, 293  
     resting mPAP, 293  
     right heart catheterization, 293  
   modified Borg dyspnea scale, 291  
   noninvasive testing, 292  
   pulmonary capillary wedge pressure, 309  
   pulmonary function testing, 292  
   right heart catheterization, 289  
   6-minute walk distance (6MWD), 291  
   symptoms, 291  
   transthoracic echocardiography, 292  
   tricuspid annular plane systolic excursion, 292  
   ventilation-perfusion scan, 292  
   WHO classification system, 289, 290  
 Pulmonary vascular resistance (PVR), 34, 52, 310, 322  
 Pulmonary vasculature, afterload, 33–34  
 Pulmonary venous hypertension, 19  
*Pulsus alternans*, 346  
 Pulsus paradoxus, 142, 242–245, 255–256
- Q**  
 Quantitative coronary angiography (QCA), 351
- R**  
 Real-time gradient echo CMR, 200  
 Regurgitant volume per beat, 178, 179  
 Relative CFR, 353

- Renin–angiotensin–aldosterone system (RAAS)  
 activation of, 105  
 blockade, 61  
 inhibitor mechanism, 61–63  
 mechanism of action, 62  
 role, 61
- Restrictive cardiomyopathy (RCM), 251  
 cardiac magnetic resonance imaging, 261, 262  
 causes, 255  
 chest radiography, 256  
 computed tomography, 261  
 Doppler echocardiography, 256  
 electrocardiography, 256  
 features, 268  
 global longitudinal strain, 260  
 hemodynamic assessment, 264  
 history/clinical presentation, 255  
 Kussmaul’s sign, 269  
 left and right heart catheterization, 264  
 mitral annular velocity, 258  
 mitral inflow, 269  
 pathophysiology, 252–254  
 physical examination, 255  
 pulmonary and hepatic venous flows, 259  
 tissue Doppler imaging (TDI), 256  
 trans-mitral flow velocity pattern, 256  
 transthoracic echocardiography, 256
- Rheumatic fever, 279
- Rheumatic mitral valve disease, 286
- Right atrial pressure, 6
- Right atrial pressure waveform, 6–7
- Right heart catheterization (RHC), 289
- Right ventricular (RV) preload estimation, 89
- Right ventricular systolic pressure (RVSP), 178
- S**
- Sacubitril/valsartan, 105, 106, 109  
 absorption, 109  
 hemodynamic impact of, 109
- Sarcoendoplasmic reticulum calcium ATPase (SERCA)  
 pump, 43
- Scimitar syndrome, 191
- Secondary mitral regurgitation, 283
- Secundum atrial septal defect, 178
- Sepsis  
 definition, 147  
 severe, 147
- Septic shock, 147
- Shock  
 diagnostic evaluation, 342–344  
 echocardiography, 343  
 epidemiology, 337  
 etiology, 338  
 hemodynamic assessment, 344  
 arterial hypoxia, 347  
 cardiac output, 344  
 elevated PCWP, 345  
 intra-arterial pressure waveform, 345  
 mixed venous oxygen concentration, 345  
 narrow pulse pressure, 345  
 narrow pulse widths, 346  
 pulmonary vascular resistance, 345  
 pulsus alternans, 347  
 systemic tissue perfusion, 344  
 systemic vascular resistance, 345  
 wide pulse pressure, 346  
 pulmonary artery catheterization, 343, 344  
 severe sepsis, 348
- Shunt, 189  
 assessment, 232  
 definition, 232  
 fraction, 201  
 volume, 201
- Sinoatrial myocytes, 109
- Sinus venosus atrial septal defect, 301
- Sodium nitroglycerine, 68
- Sodium nitroprusside, 93
- Speckle tracking echocardiography (STE), 42, 260
- Stroke volume, 313  
 determinants, 51  
 preload effect, 51
- Surgical Pott’s shunts, 298
- Swan-Ganz catheter, 9, 54
- Sympathetic nervous system (SNS) activation, 105
- Syncope, 149
- Systemic inflammatory response state (SIRS), 146, 147
- Systemic lupus erythematosus (SLE), 237
- Systemic vascular resistance (SVR), 34, 52, 310
- Systolic anterior motion (SAM), 149
- Systolic area index, 265
- Systolic flow murmur, 145
- Systolic Heart Failure Treatment with the If-inhibitor  
 Ivabradine (SHIFT) Trial, 111
- T**
- Tachyphylaxis, 93
- Tamponade  
 cardiac, 240  
 constriction, 245, 249  
 Doppler evaluation, 244  
 echocardiographic evaluation, 243  
 findings in, 244  
 hepatic vein flow pattern, 249  
 initial treatment strategy, 249  
 low-pressure, 242  
 pathophysiology of, 240–241  
 pericardial, 247–249  
 sign of, 248, 249  
 stages of, 241
- TandemHeart, 123
- Targeted PAH pharmacotherapies, 297
- Thermodilution cardiac output curves, 55
- Thermodilution method, 54–55
- 3D echocardiography, 178
- Total peripheral resistance (TPR), 34–35
- Total peripheral vascular resistance, 25
- Transesophageal echocardiography (TEE), 261
- Transient constrictive pericarditis, 261



Transmural pressure, 240  
Transpulmonary thermodilution technique, 56  
Tricuspid regurgitation (TR), 19, 148  
2D echocardiography, 256

## V

Valsartan Heart Failure Trial (Val HeFT), 106  
Valvular heart disease, 192–194  
  aortic regurgitation, 274–278  
  aortic stenosis, 271–275  
  mitral regurgitation, 282–285  
  mitral stenosis, 278–282  
Valvular regurgitation, 234, 276  
Valvular stenosis, 232, 272  
Vascular hemodynamics, 196  
Vascular resistance, 231–232  
Vasoconstricting neurohormones, 310  
Vasoconstrictors  
  phenylephrine, 98–97  
  vasopressin, 98–99  
Vasodilation, 74  
Vasodilator therapy  
  dobutamine, 94–95  
  hemodynamic effects, 91–99  
  hypertension treatment, 91  
  inotropes, 94  
  intravenous calcium channel blockers, 93  
  isoproterenol, 95  
  levosimendan, 96  
  milrinone, 95–96  
  nitroglycerin, 91–92  
  sodium nitroprusside, 93  
Vasogenic shock, 53  
Vasopressors  
  characteristics, 96  
  dopamine, 97  
  epinephrine, 97  
  norepinephrine, 97  
Veno-arterial extra-corporeal membrane oxygenation  
  (VA-ECMO), 130

  cardiogenic shock, 131  
  characteristics, 124  
  configurations, 125  
  hemodynamic effects, 124  
  indications and contraindications, 127  
  management, 130  
  risks and limitations, 126  
Venoconstriction, 8  
Venodilation, 8  
Venodilators, 68  
Venous return, 4, 8  
Ventricular dilation, 52  
Ventricular ejection fraction, 38  
Ventricular interdependence phenomenon, 252  
Ventricular pressure-volume loops, 68  
Ventricular septal defect (VSD), 189–190  
Ventricular septal rupture, 349  
Ventricular septal shift (VSS), 256  
Ventricular wall forces, 23  
Ventricular wall stress  
  vs. arterial input impedance, 28–32  
  definition, 28  
Ventriculo-arterial coupling, 26  
  and pressure-volume loops, 30–31  
Ventriculo-arterial mismatch, 27  
Ventriculography, 285  
Verapamil, 82  
Volume assessments, 3  
Volume overload, physical findings, 206  
Volume status assessment, 205

## W

Water hammer pulse, 145  
Wave reflection, systolic pressure profile, 27  
Waveforms  
  intra-cardiac pressure, 9  
  left ventricular assist device (LVAD) flow, 18  
Wave-free period (WFP), 357  
Windkessel effect, 25, 26, 37  
Wood units, 34